This 2006 narrative review by Katz quantifies the socioeconomic burden of lumbar disc disorders and low-back pain in the United States. It examines both who is at risk (socioeconomic risk factors) and what the disorder costs society (direct and indirect costs). The central question: where does the money go, who drives it, and when should we intervene?
80% return within 1 month
90% return by 3 months
The clock starts ticking the moment a patient with low-back pain fails to return to work within the first month. At 6 months off work, the return-to-work probability is 50%. At 1 year, it is 25%. This exponential decline is the entire economic story of low-back pain — a small group of patients who never recover drives nearly all costs.
The actionable window is the subacute period: 2 weeks to 6 months. When you see a patient still out of work at 4–6 weeks, that is the moment to escalate: screen for job dissatisfaction, fear-avoidance, depression, and Workers' Compensation status, because these psychosocial factors predict disability more reliably than any imaging finding.
When counseling patients or justifying surgical referral, know these numbers: discectomy costs ~$34,000/QALY and is economically defensible. Instrumented fusion for degenerative spondylolisthesis with stenosis costs ~$3,000,000/QALY. Katz explicitly flags this as an outlier that demands scrutiny, a point that has shaped ongoing debate about the value of instrumentation in degenerative spine surgery.
This 2006 narrative review by Katz quantifies the socioeconomic burden of lumbar disc disorders and low-back pain in the United States. It examines both who is at risk (socioeconomic risk factors) and what the disorder costs society (direct and indirect costs). The central question: where does the money go, who drives it, and when should we intervene?
80% return within 1 month
90% return by 3 months
The clock starts ticking the moment a patient with low-back pain fails to return to work within the first month. At 6 months off work, the return-to-work probability is 50%. At 1 year, it is 25%. This exponential decline is the entire economic story of low-back pain — a small group of patients who never recover drives nearly all costs.
The actionable window is the subacute period: 2 weeks to 6 months. When you see a patient still out of work at 4–6 weeks, that is the moment to escalate: screen for job dissatisfaction, fear-avoidance, depression, and Workers' Compensation status, because these psychosocial factors predict disability more reliably than any imaging finding.
When counseling patients or justifying surgical referral, know these numbers: discectomy costs ~$34,000/QALY and is economically defensible. Instrumented fusion for degenerative spondylolisthesis with stenosis costs ~$3,000,000/QALY. Katz explicitly flags this as an outlier that demands scrutiny, a point that has shaped ongoing debate about the value of instrumentation in degenerative spine surgery.